Literature DB >> 8181193

Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population.

D G May1, J Porter, G R Wilkinson, R A Branch.   

Abstract

Phenotypic trait values in 166 healthy white subjects (age range, 18 to 88 years) were determined for dapsone N-hydroxylation, dapsone N-acetylation, debrisoquin 4-hydroxylation, and S-mephenytoin 4'-hydroxylation after single oral dose administration of the probe drugs dapsone (100 mg), debrisoquin (10 mg), and mephenytoin (100 mg). No associations or evidence of cosegregation were found between the individual routes of metabolism. Dapsone N-hydroxylation exhibited a unimodal distribution, with marked (tenfold) intersubject variability, and aging was associated with reduced N-oxidation. However, the other measured routes of metabolism were age independent, but intersubject variability in all of the trait measurements increased with age. In subjects younger than 50 years, S-mephenytoin 4'-hydroxylation was modestly (34%) less in men than in women. In contrast, dapsone N-acetylation, dapsone N-hydroxylation, and debrisoquin 4-hydroxylation were not influenced by gender. Previous smoking habit and alcohol consumption were not associated with a difference in any of the four routes of metabolism. Accordingly, the measured phenotypic traits of drug oxidation and N-acetylation appear to be quite robust in regard to some common demographic variabilities present in population studies, with the exception of dapsone N-hydroxylase, which is affected by aging.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8181193     DOI: 10.1038/clpt.1994.62

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

Review 1.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

2.  Effects of CYP3A inhibition on the metabolism of cilostazol.

Authors:  A Suri; W P Forbes; S L Bramer
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

Review 3.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 5.  Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.

Authors:  Alessio Provenzani; Andrew Santeusanio; Erin Mathis; Monica Notarbartolo; Manuela Labbozzetta; Paola Poma; Ambra Provenzani; Carlo Polidori; Giovanni Vizzini; Piera Polidori; Natale D'Alessandro
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 6.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  M T Kinirons; P Crome
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

7.  Predicted metabolic drug clearance with increasing adult age.

Authors:  Thomas M Polasek; Farhaan Patel; Berit P Jensen; Michael J Sorich; Michael D Wiese; Matthew P Doogue
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

Review 8.  Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.

Authors:  Rajeev K Mehlotra; Cara N Henry-Halldin; Peter A Zimmerman
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

9.  A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study.

Authors:  Ashish Sharma; Sylvie Pilote; Pierre M Bélanger; Marie Arsenault; Bettina A Hamelin
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

Review 10.  Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology.

Authors:  L L von Moltke; D J Greenblatt; J Schmider; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.